These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8832012)

  • 1. Marrow engraftment and clinical manifestations of capillary leak syndrome.
    Cahill RA; Spitzer TR; Mazumder A
    Bone Marrow Transplant; 1996 Jul; 18(1):177-84. PubMed ID: 8832012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peri-engraftment clinical abnormalities following allogeneic hematopoietic cell transplantation: a retrospective review of 216 patients.
    Choi SJ; Lee KH; Lee JH; Lee JH; Kim S; Seol M; Lee YS; Kim WK; Park CJ; Chi HS; Lee JS
    Bone Marrow Transplant; 2003 Oct; 32(8):809-13. PubMed ID: 14520426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation.
    Lee CK; Gingrich RD; Hohl RJ; Ajram KA
    Bone Marrow Transplant; 1995 Jul; 16(1):175-82. PubMed ID: 7581119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
    Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engraftment syndrome following hematopoietic stem cell transplantation.
    Spitzer TR
    Bone Marrow Transplant; 2001 May; 27(9):893-8. PubMed ID: 11436099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
    Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
    Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
    O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
    Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelium as 'novel' target of graft-versus-host disease.
    Tichelli A; Gratwohl A
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):139-48. PubMed ID: 18503982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for capillary leakage syndrome after bone marrow transplantation.
    Nürnberger W; Willers R; Burdach S; Göbel U
    Ann Hematol; 1997 May; 74(5):221-4. PubMed ID: 9200994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
    List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
    Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting morbidity following hematopoietic stem cell transplantation.
    Gordon B; Haire W; Ruby E; Kotulak G; Stephens L; Kessinger A; Armitage J
    Bone Marrow Transplant; 1997 Mar; 19(5):497-501. PubMed ID: 9052918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality.
    Schots R; Kaufman L; Van Riet I; Lacor P; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 1998 Jul; 22(1):79-85. PubMed ID: 9678800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Engraftment syndrome in hematopoietic stem cell transplantation].
    Miwa A
    Ryoikibetsu Shokogun Shirizu; 1998; (22 Pt 3):595-600. PubMed ID: 9851227
    [No Abstract]   [Full Text] [Related]  

  • 20. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course.
    Avery R; Kalaycio M; Pohlman B; Sobecks R; Kuczkowski E; Andresen S; Mossad S; Shamp J; Curtis J; Kosar J; Sands K; Serafin M; Bolwell B
    Bone Marrow Transplant; 2005 Mar; 35(5):497-9. PubMed ID: 15640812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.